STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Cytek Biosciences to Participate in Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Cytek Biosciences (Nasdaq: CTKB), a leading cell analysis solutions company, has announced its participation in three upcoming investor conferences in August and September 2025.

The company will participate in: the UBS Precision Medicine Summit with a panel discussion on August 14, the Wells Fargo Healthcare Conference with 1x1 investor meetings on September 4, and the Morgan Stanley Global Healthcare Conference with a fireside chat on September 10. Live and archived webcasts for the UBS and Morgan Stanley events will be available on the company's investor relations website.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

FREMONT, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the following investor conferences.

  • UBS Precision Medicine Summit in Dana Point, CA
    Panel discussion: New Dimensions in Proteomics and Cellular Research on Thursday, August 14, 2025, at 8:15 a.m. Pacific Time / 11:15 a.m. Eastern Time
  • Wells Fargo Healthcare Conference in Boston, MA
    Participating in investor 1x1 meetings on Thursday, September 4, 2025
  • Morgan Stanley 23rd Annual Global Healthcare Conference in New York, NY
    Fireside chat on September 10, 2025, at 7:00 a.m. Pacific Time /10:00 a.m. Eastern Time


Interested parties may access live and archived webcasts of the presentations for the UBS and Morgan Stanley events referenced above on the “Investors” section of the company website at: investors.cytekbio.com.

About Cytek Biosciences, Inc.
Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP®) technology. Cytek’s novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek’s platform includes: its core FSP instruments, the Cytek Aurora™, Northern Lights™, Cytek Aurora™ CS and Cytek Aurora™ Evo systems; the Cytek Orion™ reagent cocktail preparation system; the Enhanced Small Particle™ (ESP™) detection technology; the flow cytometers and imaging products under the Amnis® and Guava® brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at www.cytekbio.com.

Cytek’s products are for research use only and not for use in diagnostic procedures (other than Cytek’s Northern Lights-CLC system and certain reagents, which are available for clinical use only in China and the European Union).

Cytek, Full Spectrum Profiling, FSP, Cytek Aurora, Northern Lights, Enhanced Small Particle, ESP, Cytek Orion, Amnis and Guava are trademarks of Cytek Biosciences, Inc.

In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Cytek uses its website (www.cytekbio.com), LinkedIn page and X (formerly Twitter) account as channels of distribution of information about its company, products, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Cytek may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Cytek’s website, LinkedIn page, and X account in addition to following its SEC filings, news releases, public conference calls and webcasts.

Media Contact:
Stephanie Olsen
Lages & Associates
(949) 453-8080
stephanie@lages.com

Investor Contact:
Paul Goodson
Head of Investor Relations
Cytek Biosciences
pgoodson@cytekbio.com


FAQ

When is Cytek Biosciences (CTKB) presenting at the Morgan Stanley Healthcare Conference 2025?

Cytek Biosciences will participate in a fireside chat at the Morgan Stanley Conference on September 10, 2025, at 7:00 a.m. Pacific Time (10:00 a.m. Eastern Time).

Where can I watch Cytek Biosciences' (CTKB) investor conference presentations?

Live and archived webcasts of the UBS and Morgan Stanley presentations can be accessed on the 'Investors' section of Cytek's website at investors.cytekbio.com.

What investor conferences is Cytek Biosciences (CTKB) attending in 2025?

Cytek is attending three conferences: the UBS Precision Medicine Summit (August 14), Wells Fargo Healthcare Conference (September 4), and Morgan Stanley Global Healthcare Conference (September 10).

What type of company is Cytek Biosciences (CTKB)?

Cytek Biosciences is a leading cell analysis solutions company listed on the Nasdaq stock exchange.
Cytek Biosciences, Inc.

NASDAQ:CTKB

CTKB Rankings

CTKB Latest News

CTKB Latest SEC Filings

CTKB Stock Data

716.04M
115.96M
9.24%
63.36%
4.47%
Medical Devices
Laboratory Analytical Instruments
Link
United States
FREMONT